Aldeyra Therapeutics Inc

詳細情報 Aldeyra Therapeutics Inc 企業名

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

企業情報

企業コードALDX

会社名Aldeyra Therapeutics Inc

上場日May 02, 2014

最高経営責任者「CEO」Dr. Todd C. Brady, M.D., Ph.D.

従業員数9

証券種類Ordinary Share

決算期末May 02

本社所在地131 Hartwell Avenue

都市LEXINGTON

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号02421

電話番号17817614904

ウェブサイトhttps://www.aldeyra.com/

企業コードALDX

上場日May 02, 2014

最高経営責任者「CEO」Dr. Todd C. Brady, M.D., Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Todd C. Brady, M.D., Ph.D.

President, Chief Executive Officer, Director

1.42M

+23.16%

Dr. Richard H. Douglas, Ph.D.

Independent Chairman of the Board

125.00K

--

Mr. Martin J. Joyce

Independent Director

23.97K

--

Dr. Gary M. Phillips, M.D.

Independent Director

14.81K

--

Dr. Neal S. Walker

Independent Director

--

Dr. Stephen G. Machatha, Ph.D.

Chief Development Officer

--

Dr. Ben R. Bronstein, M.D.

Independent Director

--

Ms. Nancy B. Miller-Rich

Independent Director

--

Mr. William (Chip) Clark

Independent Director

--

Mr. Michael (Mike) Alfieri

Principal Financial Officer and Principal Accounting Officer

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Todd C. Brady, M.D., Ph.D.

President, Chief Executive Officer, Director

1.42M

+23.16%

Dr. Richard H. Douglas, Ph.D.

Independent Chairman of the Board

125.00K

--

Mr. Martin J. Joyce

Independent Director

23.97K

--

Dr. Gary M. Phillips, M.D.

Independent Director

14.81K

--

Dr. Neal S. Walker

Independent Director

--

Dr. Stephen G. Machatha, Ph.D.

Chief Development Officer

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Knoll Capital Management, LLC

9.14%

Perceptive Advisors LLC

6.76%

BlackRock Institutional Trust Company, N.A.

5.91%

The Vanguard Group, Inc.

5.85%

Ardsley Advisory Partners LP

3.42%

他の

68.92%

株主統計

比率

Knoll Capital Management, LLC

9.14%

Perceptive Advisors LLC

6.76%

BlackRock Institutional Trust Company, N.A.

5.91%

The Vanguard Group, Inc.

5.85%

Ardsley Advisory Partners LP

3.42%

他の

68.92%

種類

株主統計

比率

Hedge Fund

19.07%

Investment Advisor

18.01%

Investment Advisor/Hedge Fund

11.10%

Private Equity

6.76%

Individual Investor

3.10%

Research Firm

2.16%

Family Office

0.25%

Pension Fund

0.18%

Bank and Trust

0.09%

他の

39.28%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

295

35.94M

60.00%

-7.70M

2025Q1

315

40.31M

67.37%

-4.94M

2024Q4

306

39.84M

66.72%

-5.42M

2024Q3

295

38.52M

64.82%

-5.60M

2024Q2

290

37.23M

62.65%

-8.21M

2024Q1

294

37.04M

62.88%

-7.70M

2023Q4

296

36.84M

62.63%

-6.52M

2023Q3

298

39.89M

68.07%

-12.41M

2023Q2

305

41.03M

70.05%

-8.66M

2023Q1

311

38.11M

64.83%

-12.64M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Knoll Capital Management, LLC

5.48M

9.14%

--

Mar 31, 2025

Perceptive Advisors LLC

4.88M

8.14%

-4.40M

-47.44%

Apr 03, 2025

BlackRock Institutional Trust Company, N.A.

3.41M

5.7%

-50.91K

-1.47%

Mar 31, 2025

The Vanguard Group, Inc.

3.72M

6.21%

-38.77K

-1.03%

Mar 31, 2025

Ardsley Advisory Partners LP

1.75M

2.92%

+600.00K

+52.17%

Mar 31, 2025

AQR Capital Management, LLC

392.56K

0.66%

+321.99K

+456.32%

Mar 31, 2025

Brady (Todd C)

1.42M

2.38%

+267.69K

+23.16%

Apr 14, 2025

Kingdon Capital Management, L.L.C.

779.00K

1.3%

+779.00K

--

Mar 31, 2025

Geode Capital Management, L.L.C.

1.14M

1.9%

+18.27K

+1.63%

Mar 31, 2025

683 Capital Management LLC

476.00K

0.79%

+186.00K

+64.14%

Mar 31, 2025

詳細を見る

5.010USD

Aldeyra Therapeutics Inc

5.010

概要

企業名

金融

分析